araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer

Summary: A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease. So, discovery of different diagnostic methods that allow clinicians to identify slow-growing from potentially fast-growing disease prior to or at the time of prostate biopsy could result in early and suitable treatment for men at greatest risk, while greatly decreasing the number of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and patient worry, for those with more slow-growing disease.


Eligibility: Inclusion Criteria:
  -  Prostate cancer diagnosis prior to treatment
  -  Age 21 years or older
  -  Signed informed subject consent
  -  Prostatectomy as planned prostate cancer treatment
  Exclusion Criteria:
  -  Men who do not choose prostatectomy
  -  Men who have undergone any neoadjuvant therapy
  -  Men who have cardiac pacemakers or other implanted electronic devices
  -  Men who have any surgically implanted metal
  -  Men who have had any surgical procedure that precludes placement of endorectal probe
  -  Indication of dementia or memory issues listed on problem list
  -  Men who indicate exposure to ocular metal fragments; confirmed by positive ocular x-ray
  -  Men who are taking newly-prescribed (within 6 months of enrollment) lipid control medications

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program

Summary: Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.


Eligibility: Inclusion Criteria:
  -  Prostate Cancer patients
  -  Castration Resistant
  -  Prostatic tissue available
  -  Metastasis which may be biopsied
  Exclusion Criteria:

Relevance to patient case: possibly relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients

Summary: Glycemic variability in critically ill patients is a recognized negative prognostic factor. The molecular mechanisms determining inter-patients variability in glucose metabolism during stress are not fully understood. The Phosphatase and Tensin homolog (PTEN) is known to influence glucose homeostasis by interfering in intracellular insulin signaling.
  Aim of this study is to ascertain whether differential expression of PTEN in critically ill patients correlates with glycemic variability and clinical outcome.


Eligibility: Inclusion Criteria:
  -  trauma
  -  provision informed consent
  Exclusion Criteria:
  -  diabetes
  -  impaired fasting glucose levels

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel

Summary: Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.
  One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein.
  Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in cancer patients.
  The investigators aim to prospectively study the association between the plasma level of alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients.

Detailed description: Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.
  One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein
  Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in non small cell lung cancer patients.
  The investigators aim to prospectively study the association between the baseline plasma level of alpha 1 acid glycoprotein (measured on the first day of the first cycle of docetaxel) and the outcome (response rete, progression free survival, overall survival) of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, stomach cancer, prostate cancer, and bladder cancer.

Eligibility: Inclusion Criteria
  -  patients with metastatic cancer from lung, breast, gastric, prostate, and bladder origin
  -  patients must be treated with docetaxel based chemotherapy
  -  patients must sign an informed consent form
  Exclusion Criteria
  -  patients with metastatic cancer other than lung, breast, gastric, prostate, and bladder origin
  -  patients treated with chemotherapy other than docetaxel
  -  patients that did not sign an informed consent form

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Effect of Enhanced External Counterpulsation on Lower Urinary Tract Symptoms

Summary: The purpose of this study is to access the effects of Enhanced External Counterpulsation treatment on lower urinary tract symptoms in patients with benign prostatic hyperplasia.

Detailed description: Patients with benign prostatic hyperplasia and will be randomized into two groups: EECP intervention or not. Lower urinary tract symptoms, hemodynamic parameters, vascular endothelial function will be measured and compared

Eligibility: Inclusion Criteria:
  1. men over 18 years old;
  2. provide signed informed consent;
  3. existence of lower urinary tract symptoms
  4. agree not to use any lower urinary tract symptoms treatment at least one month;
  5. suitable for receiving EECP treatment
  Exclusion Criteria:
  1. history of long drug abuse;
  2. pelvic, spine, brain trauma or surgery;
  3. endocrine, liver, lung, kidney disease, malignancies, hematological disorders;
  4. Severe infection without effective control；
  5. lower limbs deep vein thrombosis；
  6. Large area of ulcerative rash；
  7. unsuitable for receiving EECP treatment

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks

Summary: The purpose of this study is to determine whether using the P3P website can increase decisional preparation and satisfaction, and decrease decisional conflict, in men deciding how to manage early stage prostate cancer.


Eligibility: Inclusion Criteria:
  -  Biopsy-proven diagnosis of prostate cancer, T1 or T2 of any risk level
  -  Biopsy done at enrolling site
  -  Upcoming appointment with consulting specialist at enrolling study site
  -  Able to read, write, understand English
  Exclusion Criteria:
  -  Two or more post-biopsy specialist consults
  -  Begun treatment (or active surveillance)

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Radiotherapy for Oligometastatic Prostate Cancer

Summary: The purpose of this phase II study is to evaluate the outcomes of patients treated with an investigational radiation regimen using stereotactic radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.

Detailed description: This study will serve as a component of a larger program investigating the benefits of stereotactic radiotherapy in patients with metastatic disease.
  This particular study will serve as a benchmark analysis.
  All patients will receive stereotactic radiotherapy directed at metastatic tumors.
  If primary prostate cancer is active and has not previously been treated with radiation therapy, conventional radiation therapy (6-8 weeks of daily treatment) may be recommended. The metastatic tumor will be treated at the same time.
  Hormone therapy will be recommended for all patients.
  Patients will be asked to complete questionnaires at regular intervals.

Eligibility: Inclusion Criteria:
  -  Patients with metastatic cancer of the prostate,
  -  Patients may have received prior surgery,
  -  Prior radiation therapy, androgen deprivation therapy (ADT), immunotherapy, bone metastasis directed therapy, or chemotherapy for prostate cancer.
  Exclusion Criteria:
  -  End-stage heart disease,
  -  End-stage liver disease,
  -  End-stage renal disease,
  -  End stage pulmonary disease
  -  Current brain or central nervous system metastasis.

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy

Summary: To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy.

Detailed description: 1. The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) .
  2. Venous blood (4 ml) is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are sorted by Fluorescence Activated Cell Sorting(FACS) and stored at -80°C until processing.
  3. The T-Cell Receptor/B-Cell Receptor gene expression is detected by micro-array。
  4. Estimate Immunotherapy response, time to disease progression, survival rates and clinical benefit response on patients. Response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups: sensitive and non-sensitive to immunotherapy.
  5. Compare the gene expression profile between different immunotherapy response groups to explore the mechanism that predict the DC-CIK immunotherapy response.

Eligibility: Inclusion Criteria:
  -  histologically confirmed with malignant tumor;
  -  Age: 18-80 years;
  -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
  -  At least one measurable lesion according to the RECIST criteria;
  -  Adequate bone marrow, cardiac, liver, and renal function;
  -  Life expectancy ≥2 months;
  -  Not received other anti-tumor treatment
  -  Informed consent signed
  Exclusion Criteria:
  -  previous history of other malignancies;
  -  Uncontrolled central nervous system metastases;
  -  Serious or uncontrolled concurrent medical illness.

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer

Summary: Prostate cancer is the second most incident cancer among male population worldwide. Radiation therapy by itself or along with surgery and chemotherapy are the main treatments for prostate cancer however prostate cancer cells are only modestly responsive or even unresponsive to the cytotoxic effects of radiotherapy. Recently some in vitro and in vivo studies showed radiosensitizing and radioprotective effects for curcumin. No clinical trial has been done in this area and it is not yet known whether radiation therapy is more effective with or without curcumin supplements in treating patients with prostate cancer.


Eligibility: Inclusion Criteria:
  1. Histologically confirmed adenocarcinoma of the prostate
  2. Age range of 50-80
  3. ECOG performance status 0-1
  4. Life expectancy > 5 years
  5. Must be enrolled in a social security program
  6. No other cancer, except basal cell skin cancer, that has been treated or relapsed within the past 5 years
  7. No severe uncontrolled hypertension (systolic BP ≥ 160 mm Hg or diastolic BP ≥ 90 mm Hg)
  8. No contraindication to luteinizing hormone-releasing hormone agonists
  9. No contraindication to pelvic irradiation (e.g., scleroderma, chronic inflammatory gastrointestinal disease)
  10. No hip prosthesis
  11. Must not be deprived of liberty or under guardianship
  12. No geographical, social, or psychological reasons that would preclude follow up
  Exclusion Criteria:
  1. Clinical stage T3 or T4
  2. Gleason score ≥ 8
  3. Serum PSA ≥ 20 ng/mL and ≤ 100 ng/mL
  4. other prior surgery for prostate cancer
  5. concurrent participation in another clinical trial which would require approval upon entry to this trial
  6. Gastrointestinal disorders such as IBD, reflux and peptic ulcers
  7. Any adverse reaction to curcumin

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents

Summary: This study will evaluate PF-05212384 (PI3K/mTOR inhibitor) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination.


Eligibility: Inclusion Criteria:
  -  Arm A: castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination.
  -  Arm B: Urothelial transitional cell cancer, triple negative breast cancer, ovarian cancer or non small cell lunch cancer that are candidates for a cisplatin-based combination.
  -  Arm C: Her2+ breast cancer refractory to prior herceptin or lapatinib, her2+ esophagal-gastric cancer, head and neck squamous cell cancer, or non small cell lunch cancer that are candidates for treatment with a dacomitinib-based combination.
  -  Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available.
  -  Eastern Cooperative Oncology Group [ECOG] performance must be 0 or 1.
  -  Adequate bone marrow, renal and liver function.
  Exclusion Criteria:
  -  Patients with known symptomatic brain metastases.
  -  Chemotherapy, radiotherapy, biologics or investigational agent within 4 weeks of the lead-in dose.
  -  Major surgery within 4 weeks of the baseline disease assessments.
  -  >2 prior regimens containing cytotoxic chemotherapy in the metastatic setting.
  -  Active bacterial, fungal or viral infection.
  -  Uncontrolled or significant cardiovascular disease.

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Summary: This study is designed to evaluate the efficacy and safety of Naftopidil in Korean male patients with with lower urinary tract symptoms associated with benign prostatic hyperplasia.
  The investigators hypothesized that Naftopidil which came onto marcket in Japan would effect in improvement of voiding and storage difficulty.
  Design:
  Placebo-controlled, Randomized, Double-blind, Double-dummy, Parallel group, Fixed dose design


Eligibility: Inclusion Criteria:
  -  Male patients aged 4 years or more diagnosed with BPH
  Exclusion Criteria:
  -  subjects with uncontrolled blood pressure
  -  subjects with hepatic or renal dysfunction
  -  subjects with prostate cancer
  -  Had treatments for BPH using other alpha receptor antagonists within 2 weeks

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer

Summary: To development of clinical assessment technique using multi-radiotracer positron emission tomography/magnetic resonance (PET/MR) in prostate cancer
  -  to establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer
  -  to establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer and early detection of recurrent prostate cancer

Detailed description: To establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer
  -  Recruiting 30 patients with prostate cancer ahead to radical prostatectomy
  -  PET/MR using 18F-choline with dedicated prostate MRI in all patients
  -  PET/MR using 18fluoride(F)-fluorodeoxyglucose(FDG)in all patients after 2-7 days
  -  PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR
  -  outcome assessment: comparison of scan time, image quality, tumor detection rate, standardized uptake values of lesions
  -  establishing optimal imaging technique for prostate PET/MR
  To establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer
  -  comparison of findings on PET/MR, MRI and PET/CT with pathological mapping after radical prostatectomy
  -  outcome assessment: accuracy of PET/MR for localization and staging of prostate cancer compared with MRI only and PET/CT only
  To establish the imaging biomarker using PET/MR for early detection of recurrent prostate cancer
  -  Recruiting 15 patients with recurrent prostate cancer treated by surgery, hormone, or radiation therapy
  -  Recruiting 15 patients with treated prostate cancer without recurrence
  -  PET/MR using 18F-choline with dedicated prostate MRI in all patients
  -  PET/MR using 18F-FDG in all patients after 2-7 days
  -  PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR
  -  comparison of findings on PET/MR, MRI, and PET/CT with clinical data in two patient groups with or without recurrent prostate cancer
  -  outcome assessment: accuracy of PET/MR for early detection and localization of recurrent prostate cancer compared with MRI only and PET/CT only

Eligibility: Inclusion Criteria:
  -  patient with prostate cancer before treatment
  -  patient with prostate cancer treated
  -  patient with prostate cancer recurrent
  Exclusion Criteria:
  -  patient with contraindication for MRI
  -  Patient with severe renal impairment

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer

Summary: There is now overwhelming evidence documenting the efficacy of psychotherapy in the treatment of depression in the general population. Surprisingly, however, given the high prevalence of depression in cancer patients, there are very few studies on the efficacy of psychotherapy in this population. Published studies of psychotherapy in cancer patients generally include patients with high heterogeneity of psychiatric diagnosis and frequently include patients without a psychiatric diagnosis, with the aim of preventing the appearance of a psychiatric disorder. This heterogeneity complicates the interpretation of the efficacy and specificity of these interventions. Specifically, the efficacy of psychotherapy for major depression in patients with cancer is unknown.

Detailed description: Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.
  We will test the efficacy of IPT using a variety of outcome measures at different time points of the treatment. Those scales will evaluate the patient's depressive symptoms, psychosocial functioning and quality of life. Patients that are deemed eligible for the study will have IPT for twelve weeks. Patients will receive twelve 50-minute sessions over 16 weeks. To facilitate access to treatment, sessions 1,2,3,4, 8 and 12 will be in person, while all others will in be person or over the telephone according to the patient's choice. Sessions will be audiotaped and periodically reviewed by experienced supervisors to assess therapist's adherence to IPT technique. This taping will be optional and is covered in a separate consent form. This pilot study is to prove feasibility and acceptability of IPT in this population and to show preliminary efficacy.

Eligibility: Inclusion Criteria:
  -  A primary psychiatric diagnosis of Major Depressive Disorder as defined by DSM-IV
  -  Diagnosis of prostate, colorectal, lung or pancreatic cancer (stage 1-4)
  -  A score of 16 or above in the 17-item HAM-D (Hamilton depression scale)
  -  Male or female ages 18-75.
  -  Ability to give consent
  -  English and/ or Spanish Speaking
  Exclusion Criteria:
  -  Lifetime history of psychosis or bipolar disorder
  -  History of substance abuse or dependence in the three months prior to the study.
  -  Current suicide risk.
  -  Patients who have ever failed IPT in the context of cancer.
  -  Patients who are receiving effective medication for depression
  -  Patients with T3, T4 and THS abnormal values

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Prostate Metabolomic Study

Summary: Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or hormonal therapy. Clinical prognosis relates to stage and grade of disease. Recent advances in omic analysis may offer additional information to the physician about prognosis and radiation response. We propose to establish a protocol to incorporate omic analysis into the evaluation and treatment of patients with prostate cancer.


Eligibility: Inclusion Criteria:
  -  Males who are older than 18 years old,
  -  with clinically localized prostate cancer
  -  are receiving radiation therapy
  Exclusion Criteria:

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate (ATP) Inhibitor

Summary: The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using an Adenosine-5'-triphosphate(ATP)inhibitor.


Eligibility: Inclusion Criteria:
  -  Clinical diagnosis of prostate cancer
  -  Referred to the study by their treating physician
  Exclusion Criteria:
  - Any type of treatment before starting study

Relevance to patient case: not relevant